Showing 3,781 - 3,800 results of 112,027 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 1.48s Refine Results
  1. 3781

    Data Sheet 10_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

    Published 2025
    “…EC<sub>50</sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<sub>0−3d</sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”
  2. 3782

    Image 6_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

    Published 2025
    “…EC<sub>50</sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<sub>0−3d</sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”
  3. 3783

    Data Sheet 1_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

    Published 2025
    “…EC<sub>50</sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<sub>0−3d</sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”
  4. 3784

    Data Sheet 4_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture... by Vaskar Das (21529538)

    Published 2025
    “…EC<sub>50</sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<sub>0−3d</sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”
  5. 3785
  6. 3786
  7. 3787
  8. 3788
  9. 3789
  10. 3790
  11. 3791
  12. 3792
  13. 3793

    Steady state voltage, concentrations and electrochemical potentials for the nanopore in Fig 5a. by Liesbeth van Oeffelen (511929)

    Published 2015
    “…<p>The values shown are those in a plane through the axis of the nanopore, with <i>V</i><sub><i>L</i></sub>−<i>V</i><sub><i>R</i></sub> = 0.5 V and a surface charge density of −50mC/m<sup>2</sup>. …”
  14. 3794
  15. 3795
  16. 3796
  17. 3797
  18. 3798
  19. 3799
  20. 3800

    Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5‑<i>a</i>]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators by Shuai Wang (109515)

    Published 2020
    “…In this work, we reported the structure-based design of triazolo­[1,5-<i>a</i>]­pyrimidines as new ABCB1 modulators, of which <b>WS-691</b> significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC<sub>50</sub> = 22.02 nM). …”